Your browser doesn't support javascript.
loading
CSF Biomarkers of Alzheimer Disease in Patients With Concomitant α-Synuclein Pathology.
Quilico Cousins, Katheryn Alexandra; Arezoumandan, Sanaz; Shellikeri, Sanjana; Ohm, Daniel; Shaw, Leslie M; Grossman, Murray; Wolk, David; McMillan, Corey T; Chen-Plotkin, Alice; Lee, Edward; Trojanowski, John Q; Zetterberg, Henrik; Blennow, Kaj; Irwin, David John.
Afiliação
  • Quilico Cousins KA; Department of Neurology, Perelman School of Medicine, Philadelphia, PA, USA; katheryn.cousins@pennmedicine.upenn.edu.
  • Arezoumandan S; Department of Neurology, Perelman School of Medicine, Philadelphia, PA, USA.
  • Shellikeri S; Department of Neurology, Perelman School of Medicine, Philadelphia, PA, USA.
  • Ohm D; Department of Neurology, Perelman School of Medicine, Philadelphia, PA, USA.
  • Shaw LM; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
  • Grossman M; Department of Neurology, Perelman School of Medicine, Philadelphia, PA, USA.
  • Wolk D; Department of Neurology, Perelman School of Medicine, Philadelphia, PA, USA.
  • McMillan CT; Department of Neurology, Perelman School of Medicine, Philadelphia, PA, USA.
  • Chen-Plotkin A; Department of Neurology, Perelman School of Medicine, Philadelphia, PA, USA.
  • Lee E; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
  • Trojanowski JQ; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
  • Zetterberg H; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Blennow K; Department of Neurodegenerative Disease, Institute of Neurology, University College London, London, UK.
  • Irwin DJ; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Neurology ; 2022 Aug 30.
Article em En | MEDLINE | ID: mdl-36041863
BACKGROUND AND OBJECTIVES: Cerebrospinal fluid (CSF) biomarkers amyloid-ß42 (Aß42), phosphorylated tau (p-tau181), total tau (t-tau) and neurogranin (Ng) can diagnose Alzheimer's disease (AD) in life. However, it is unknown if CSF concentrations, and thus their accuracies, are affected by concomitant pathologies common in AD, such as α-synuclein (αSyn). Our primary goal was to test if biomarkers in patients with AD are altered by concomitant αSyn. We compared CSF Aß42, p-tau181, t-tau and Ng levels across autopsy-confirmed AD and concomitant AD and αSyn (AD+αSyn). Antemortem CSF levels were related to postmortem accumulations of αSyn. Finally, we tested how concommitant AD+αSyn affected diagnostic accuracy of two CSF-based strategies: the ATN framework and the t-tau/Aß42 ratio. METHODS: Inclusion criteria were neuropathologic diagnoses of AD, mixed AD+αSyn, and αSyn. A convenience sample of non-impaired controls were selected with available CSF and a mini mental state exam (MMSE)≥27. αSyn without AD and controls were included as reference groups. Analyses of covariance (ANCOVAs) tested planned comparisons were CSF Aß42, p-tau181, t-tau, and Ng differences across AD and AD+αSyn. Linear models tested how biomarkers were altered by αSyn accumulation in AD, accounting for pathologic amyloid-ß and tau. Receiver operating characteristic and area under the curve (AUC), including 95% confidence intervals (CI), evaluated diagnostic accuracy. RESULTS: Participants were 61 AD, 39 mixed AD+αSyn, 20 αSyn, and 61 Controls. AD had similar median age (73 [IQR=12]), MMSE (23 [IQR=9]), and sex distribution (Male=49%) compared to AD+αSyn age (70 [IQR=13]; p=0.3), MMSE (25 [IQR=9.5]; p=0.19), and sex distribution (Male=69%; p=0.077). ANCOVAs showed AD+αSyn had lower p-tau181 (F(1,94)=17, p=0), t-tau (F(1,93)=11, p=0.0004), and Ng levels (F(1,50)=12, p=0.0004) than AD; there was no difference in Aß42 (p=0.44). Models showed increasing αSyn related to lower p-tau181 (ß=-0.26, SE=0.092, p=0.0065), t-tau (ß=-0.19, SE=0.092, p=0.041), and Ng levels (ß=-0.2, SE=0.066, p=0.0046); αSyn was not a significant factor for Aß42 (p=1). T-tau/Aß42 had the highest accuracy when detecting AD, including mixed AD+αSyn cases (AUC=0.95; CI=0.92 to 0.98). DISCUSSION: Findings demonstrate that concomitant αSyn pathology in AD is associated with lower CSF p-tau181, t-tau, and Ng levels, and can affect diagnositic accuracy in AD patients.

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article